Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00867230 · ClinicalTrials.gov registry record · Phase 1
FTS Study in Patients With Advanced Hematologic Malignancies
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00867230: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00867230 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 18 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00867230, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
Primary Objective: Determining the maximum tolerated dose (MTD) and pharmacokinetics (PK) of FTS (S-Trans, Trans-Farnesylthiosalicylic Acid) after daily oral administration on Days 1 through 21 of a 28-Day cycle to patients with advanced hematologic malignancies that have progressed following effective therapy or for which no effective therapy exists.
Interventions
- DRUG FTS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2006-05 |
| Est. Completion | 2009-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00867230
The ClinicalTrials.gov registry entry for NCT00867230 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FTS is the first listed.
NCT00867230 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00867230 about?
NCT00867230 is a clinical study titled "FTS Study in Patients With Advanced Hematologic Malignancies". Primary Objective: Determining the maximum tolerated dose (MTD) and pharmacokinetics (PK) of FTS (S-Trans, Trans-Farnesylthiosalicylic Acid) after daily oral administration on Days 1 through 21 of a 28-Day cycle to patients with advanced hematologic malignancies that have progressed following effec...
What is the current status of trial NCT00867230?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2006-05. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00867230?
The interventions under investigation include: FTS (DRUG).
Who is sponsoring clinical trial NCT00867230?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.